Rigor Reviewed

Rigor-Reviewed Manuscript

Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.

Name: Αlpha¹ Rigor Record — Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.
Item: Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.
Rating: 94
Author: Αlpha¹

Theodore DA, Mayer BT, Rolle CP, DeJesus E, Ackerman ME, Seaman MS, Weiner JA, Mohri H, Huang Y, Gray B, Chang J, Gerber MW, Yu J, Luo Y, Padte NN, Yin MT, Barin B, Greene R, Palmer S, Pazmino A, Benitez J, Dorr C, McNairy M, DiRenzo J, Orzell CV, Ho DD, Hyrien O, Sobieszczyk ME

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.75★ (Weak), 0 critical, 7 high issues for “Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingStudy design partially met−0.25★
CitationsUnresolved reference−0.25★
LinksDead data/code link−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No reported statistical tests were found to recompute.

Problems surfaced7 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Study-design details incomplete (controls, blinding, power)Assessed

Broken references and links2

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Dead data/code linksRecomputed
References not resolvable to a published paperRecomputed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 1 trial of a bispecific bnAb, with strong scientific premise, ethical approvals, data/code sharing, and reporting transparency. The main weakness is incomplete reporting of study design elements (randomization method, blinding, power analysis), which is typical for phase 1 but should be documented. Minor copyedit issues and a potential internal inconsistency in Table 2 warrant attention.

Both reviewers classified the study as interventional; no divergence. The statistics verification component found no recomputable tests (total=0), so statistical correctness was not machine-verified; only descriptive statistics and PK/PD modeling were assessed. The citation check flagged one reference not found in registry (Monolix Documentation), which is a potential fabrication signal. The integrity check flagged a potential internal contradiction in Table 2 regarding group sizes.

6 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites extensive prior research on bnAbs, bispecific antibodies, and the specific 10E8.4/iMab antibody, including its potency and breadth. The rationale for the study is clearly linked to the need for long-acting HIV prevention and treatment options. The paper acknowledges limitations of prior work, such as the need for combination therapy and the challenges of immunogenicity, and addresses them in the study design.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior work on broadly neutralizing antibodies and the specific bispecific antibody, and provides a clear rationale for the study.

Evidence

paraphrase[Introduction, paragraph 1-3]

“Broadly neutralizing antibodies (bnAbs) are a promising tool to control HIV viremia, reduce the size of the viral reservoir, and prevent HIV acquisition.”

paraphrase[Introduction, paragraph 1]

“To end the HIV epidemic, it will be essential to expand the portfolio of long-acting options that are safe, tolerable and scalable so that people who stand to benefit can choose the option that works best for them.”

paraphrase[Introduction, paragraph 2; Discussion, paragraph 5]

“Realizing the full potential of bnAbs will likely require combination therapy (for example, using multiple bnAbs that bind different targets) or bi- or tri-specific bnAb therapy (single molecules that bind multiple targets).”

PASSReviewer 2· 90% conf

The paper establishes a strong scientific foundation by citing prior work on bnAbs, bispecific antibodies, and the specific 10E8.4/iMab construct, and provides a clear rationale for the study.

Evidence

paraphrase[Introduction, paragraph 1-3]

“Broadly neutralizing antibodies (bnAbs) are a promising tool to control HIV viremia, reduce the size of the viral reservoir, and prevent HIV acquisition.”

paraphrase[Introduction, paragraph 3]

“The bispecific bnAb 10E8.4/iMab, one of the most potent and broad HIV bnAbs developed to date, neutralizes nearly all circulating HIV-1 strains tested and showed efficacy in preventing and treating HIV-1 in a humanized mouse model.”

absence[Introduction]

Limitations of prior research are not explicitly discussed.

The trial is described as 'partially randomized' with only arm 4 being randomized to active or placebo. The randomization method is not specified (e.g., computer-generated, block). Blinding is not mentioned; it is likely open-label for the non-randomized arms, but this is not explicitly stated. No a priori power analysis is reported, which is common for phase 1 trials but still a limitation. Inclusion/exclusion criteria are described in detail. Outlier handling is not explicitly described, but the analysis population (safety population) is defined. Controls are present (placebo in arm 4). Independent replication is not applicable for a single phase 1 trial.

Sub-criteria

controlsADEQUATE

power analysisNOT REPORTED

blinding levelsNOT REPORTED

outlier handlingINADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodNOT REPORTED

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

The study design is a phase 1 dose-escalation trial with partial randomization, but randomization method and blinding are not fully described, and no power analysis is reported.

Evidence

absence[Methods, Study design and participants]

Randomization method is not described.

absence[Methods, Study design and participants]

Blinding is not mentioned.

absence[Methods, Statistical analysis]

No power analysis is reported.

PASSReviewer 2· 85% conf

The study design is appropriate for a phase 1 dose-escalation trial, with randomization only in arm 4, clear eligibility criteria, and a pre-specified primary outcome. Blinding is not described, but the open-label design is typical for such trials.

Evidence

direct quote[Abstract]

“In arm 4, PLWoH were randomized to receive 10E8.4/iMab or placebo 2.5 mg kg −1 SC or 10 mg kg −1 SC ( n = 9 each).”